Financial Lp Hrt Acquires 7,851 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt acquired 7,851 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were bought at an average price of $3.54 per share, with a total value of $27,792.54. Following the completion of the transaction, the insider directly owned 90,407 shares in the company, valued at approximately $320,040.78. The trade was a 9.51% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total value of $31,667.22.
• On Wednesday, July 1st, Financial Lp Hrt purchased 3,959 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average cost of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt purchased 6,755 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average cost of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt acquired 25,836 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average cost of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Stock Up 9.5%

SHPH opened at $3.57 on Thursday. The firm has a market cap of $2.28 million, a P/E ratio of -0.07 and a beta of 0.29. The business’s fifty day simple moving average is $5.30 and its 200 day simple moving average is $10.27. Shuttle Pharmaceuticals Holdings, Inc. has a 52 week low of $2.90 and a 52 week high of $55.90.

Wall Street Analysts Forecast Growth

SHPH has been the topic of several recent analyst reports. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, July 4th. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Trading of Shuttle Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Connective Capital Management LLC acquired a new position in shares of Shuttle Pharmaceuticals during the 3rd quarter valued at about $357,000. Ikarian Capital LLC acquired a new stake in shares of Shuttle Pharmaceuticals in the fourth quarter worth approximately $124,000. Boothbay Fund Management LLC purchased a new stake in Shuttle Pharmaceuticals in the fourth quarter valued at approximately $37,000. Finally, Geode Capital Management LLC acquired a new position in Shuttle Pharmaceuticals during the fourth quarter worth approximately $26,000. Hedge funds and other institutional investors own 4.58% of the company’s stock.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .